(a)
| Reference | Total number (Paricalcitol/placebo) |
Etiology of CKD | |||||
|---|---|---|---|---|---|---|---|
| DM | no DM | Treatment | Dosing regimen | Route of administration | Age | ||
| [4] | 55 (28/27) | 26 | 29 | 6-month | 1 ug/d and 2 ug/d | Oral | 18–85 |
| [5] | 24 (16/8) | 13 | 11 | 1-month | 1 ug/d and 2 ug/d | Oral | >18 |
| [6] | 118 (57/61) | 79 | 4 | 24-week | 1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIW | Oral | ≥18 |
| [7] | 78 (40/38) | — | — | 12-week | 0.04 ug/kg TIW | Intravenous | 22–90 |
| [8] TIW | 145 (72/73) | 88 | 57 | 24-week | 2 ug TIW and 4 ug TIW | Oral | ≥18 |
| [8] QD | 75 (35/40) | 41 | 34 | 24-week | 1 ug/d and 2 ug/d | Oral | ≥18 |
| [9] | 220 (107/113) | 129 | 91 | 24-week | 1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIW | Oral | ≥18 |
| [10] | 29 (15/14) | — | — | 12-week | 0.04 ug/kg or 0.08 ug/kg TIW | Intravenous | 2–20 |
| [11] | 88 (61/27) | — | — | 12-week | iPTH/60 TIW | Oral | ≥18 |
| [12] | 281 (186/95) | 272 | 0 | 24-week | 1 ug/d and 2 ug/d | Oral | >20 |
Reference [8] had different methods of administration and gave us the information, respectively.
TIW: treatment with Paricalcitol or placebo thrice weekly.
QD: treatment with Paricalcitol or placebo once a day.